Navigation Links
Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
Date:5/9/2013

lternatively, Omeros will arrange to send you the prospectus if you request it by calling Omeros at 206-676-5000. 

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding Omeros' expectations regarding the offering announced today and the use of proceeds thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2013. G
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
2. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
3. Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
4. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
5. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
6. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
7. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
8. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
9. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
10. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
11. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
(Date:4/17/2014)... YORK April 17, 2014 EcoHealth Alliance, a ... health issues, published a comprehensive review today examining the ... Marburg virus. The review calls for improved global surveillance ... as the recent outbreak of Ebola in West Africa ... the countries of Guinea and Liberia. According to ...
(Date:4/17/2014)... a colored ribbon representing a disease. A pink ribbon is ... does one think of with lung cancer?, Although white has ... the disease, black may be the only one they think ... patients, primarily smokers between the ages of 51 to 79 ... felt by these patients, the emotional toll it can have ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2
... successfully isolated nanoparticles from human kidney stones in cell ... to be associated with nanoparticles. ,The findings, ... of Investigative Medicine, are significant because it is one ... are viable living forms that can lead to disease ...
... Research Service (ARS) scientists have reported that the newly ... to produce flour with 25% more magnesium than commercial ... of the ARS Soft Wheat Quality Research Unit at ... M. Peterson at the University of Idaho Research and ...
... shock and disappointment on hearing the news about a ... five Bulgarian nurses and one Palestinian doctor for supposedly ... ,George Bush has expressed his "disappointment" to Georgi Parvanov, ... to strive for the release of the five nurses ...
... Basic Health Needs – a Report. A newspaper on Sunday ... 1999 in the nation's largest county jail system came after ... volume of inmates, coupled with a shortage of doctors and ... waiting to be examined. ,An investigation by the ...
... scientists have identified a cell population that is a ... frontotemporal dementia//, which is as common as Alzheimer's disease ... ,Because the cells arose only recently in evolutionary ... and humans-- and are particularly abundant in humans, and ...
... California, San Diego biologists have shown that the chemical ... //of electrical activity in the developing nervous system. The ... potential as a treatment for a wide range of ... in the early on-line edition of the journal Proceedings ...
Cached Medicine News:Health News:Link Between Nanoparticles and Kidney Stones 2Health News:Link Between Nanoparticles and Kidney Stones 3Health News:Health Care Suffers at Los Angeles Jails: Report 2Health News:Study Offers Window into Human Behavior, Brain Disease 2Health News:Study Offers Window into Human Behavior, Brain Disease 3Health News:Study Offers Window into Human Behavior, Brain Disease 4Health News:Electrical Activity Alters Language Used By Nerve Cells 2Health News:Electrical Activity Alters Language Used By Nerve Cells 3
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The full body blanket provides coverage to the entire patient....
Medicine Products: